studies conducted with non-commercially available analog formulations, or trials conducted with insulin preparations that are no longer commercially available.

A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...

Merilog is a rapid-acting human insulin analog designed to reduce spikes in blood sugar levels that typically occur during mealtime. This approval extends to a 3-milliliter single-patient-use ...

Hirsch also presented meal challenge data from INHALE-3, which revealed technosphere insulin resulted in a lower postprandial glucose increase compared with rapid-acting analog insulin.

A Sanofi subsidiary has claimed FDA approval for the first biosimilar of Novo Nordisk's Novolog, an older formulation of the Danish pharma's blockbuster insulin analogue product insulin aspart.

However, the reluctance in adoption of rapid acting insulin due to the side effect, such as hypoglycemia, may hinder the growth of the industry. Conversely, untapped market and undiagnosed population ...

Use of the long-acting insulin analogs glargine and detemir does not reduce the risk of diabetic ketoacidosis in children and adolescents with type 1 diabetes mellitus (T1DM), compared with the ...

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...

Objectives: The prevalence, causes, and consequences of nocturnal hypoglycemia as well as detection and prevention strategies are reviewed, including the use of long-acting insulin analogs ...